Cargando…

High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function

PURPOSE: PTEN is an important tumor suppressor in breast cancer. Here, we examined the prognostic and predictive value of PTEN and PTEN pseudogene (PTENP1) gene expression in patients with locally advanced breast cancer given neoadjuvant chemotherapy. METHODS: The association between pretreatment PT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yndestad, Synnøve, Austreid, Eilin, Knappskog, Stian, Chrisanthar, Ranjan, Lilleng, Peer Kåre, Lønning, Per Eystein, Eikesdal, Hans Petter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387035/ https://www.ncbi.nlm.nih.gov/pubmed/28213783 http://dx.doi.org/10.1007/s10549-017-4160-5

Ejemplares similares

Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines
por: Yndestad, Synnøve, et al.
Publicado: (2017)

Adjuvant treatment: the contribution of expression microarrays
por: Lønning, Per Eystein, et al.
Publicado: (2007)

Concomitant inactivation of the p53‐ and pRB‐ functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo
por: Knappskog, Stian, et al.
Publicado: (2015)

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy
por: Eikesdal, Hans P., et al.
Publicado: (2014)

Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines
por: Huun, Johanna, et al.
Publicado: (2017)

Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved
por: Lønning, Per Eystein, et al.
Publicado: (2013)

BRCA1 methylation in newborns: genetic disposition, maternal transfer, environmental influence, or by chance only?
por: Lønning, Per Eystein, et al.
Publicado: (2018)

Chemosensitivity and p53; new tricks by an old dog
por: Lønning, Per E, et al.
Publicado: (2012)

ramr: an R/Bioconductor package for detection of rare aberrantly methylated regions
por: Nikolaienko, Oleksii, et al.
Publicado: (2021)

epialleleR: an R/Bioconductor package for sensitive allele-specific methylation analysis in NGS data
por: Nikolaienko, Oleksii, et al.
Publicado: (2023)

CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer
por: Chrisanthar, Ranjan, et al.
Publicado: (2008)

Constitutional Mosaic Epimutations - a hidden cause of cancer?
por: Lønning, Per E., et al.
Publicado: (2019)

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer
por: Knappskog, Stian, et al.
Publicado: (2012)

Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel
por: Chrisanthar, Ranjan, et al.
Publicado: (2011)

Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers
por: Bjørnslett, Merete, et al.
Publicado: (2012)

Alterations of the retinoblastoma gene in metastatic breast cancer
por: Berge, Elisabet Ognedal, et al.
Publicado: (2011)

Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
por: Løes, Inger Marie, et al.
Publicado: (2016)

Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2015)

The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer
por: Poduval, Deepak, et al.
Publicado: (2020)

Correction: The novel microRNAs hsa-miR-nov7 and hsa-miR-nov3 are over-expressed in locally advanced breast cancer
por: Poduval, Deepak, et al.
Publicado: (2021)

Inverse Regulation of EGFR/HER1 and HER2-4 in Normal and Malignant Human Breast Tissue
por: Flågeng, Marianne Hauglid, et al.
Publicado: (2013)

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk
por: Knappskog, Stian, et al.
Publicado: (2011)

DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival
por: Pedersen, Christine Aaserød, et al.
Publicado: (2022)

Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour
por: Straume, Anne Hege, et al.
Publicado: (2012)

Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer
por: Lønning, Per E., et al.
Publicado: (2022)

MDM4 SNP34091 (rs4245739) and its effect on breast‐, colon‐, lung‐, and prostate cancer risk
por: Gansmo, Liv B., et al.
Publicado: (2015)

APOBEC3A/B deletion polymorphism and cancer risk
por: Gansmo, Liv B, et al.
Publicado: (2018)

An Ultrasensitive Routine LC-MS/MS Method for Estradiol and Estrone in the Clinically Relevant Sub-Picomolar Range
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2020)

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma
por: Birkeland, Einar, et al.
Publicado: (2013)

Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens
por: Løes, Inger Marie, et al.
Publicado: (2014)

Atheroembolization and potential air embolization during aortic declamping in open repair of a pararenal aortic aneurysm: A case report
por: Dregelid, Einar Børre, et al.
Publicado: (2016)

Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers
por: Berge, Elisabet Ognedal, et al.
Publicado: (2010)

Impaired lymphatic function accelerates cancer growth
por: Steinskog, Eli Sihn Samdal, et al.
Publicado: (2016)

Strength and weakness of phase I to IV trials, with an emphasis on translational aspects
por: Lønning, Per Eystein
Publicado: (2008)

Are current development programs realising the full potential of new agents?
por: Lønning, Per Eystein
Publicado: (2010)

Tailored targeted therapy for all: a realistic and worthwhile objective?
por: Lønning, Per Eystein
Publicado: (2009)

The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian—but not endometrial cancer
por: Gansmo, Liv B., et al.
Publicado: (2016)

Prevalence of the CHEK2 R95* germline mutation
por: Knappskog, Stian, et al.
Publicado: (2016)

Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
por: Huun, Johanna, et al.
Publicado: (2017)

Assessment of tumor suppressor promoter methylation in healthy individuals
por: Poduval, Deepak B., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1ucma0oc78cna12n642jso2b8a